PLATELET INVOLVEMENT IN REFLEX CUTANEOUS VASODILATION
血小板参与反射性皮肤血管舒张
基本信息
- 批准号:7951342
- 负责人:
- 金额:$ 2.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:AgingAspirinAttenuatedBlood PlateletsBlood VesselsClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseCoupledCrossover DesignCutaneousDataDiseaseDoseDouble-Blind MethodEnzymesFeverFundingGrantHeat Stress DisordersHeatingHumanInstitutionLaser-Doppler FlowmetryMeasuresMediatingMicrodialysisNitric OxideNitric Oxide SynthaseOralPathway interactionsPharmaceutical PreparationsPlatelet ActivationPlatelet InhibitorsPlavixPrevention therapyProceduresProtein IsoformsReflex actionResearchResearch PersonnelResourcesRoleScreening procedureSiteSkinSourceTestingTissuesUnited States National Institutes of HealthVasodilationVasodilator Agentsclopidogrelmiddle agesystemic intervention
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Human aging is associated with attenuated cutaneous vasodilation (VD) during hyperthermia due to a reduction in non-nitric oxide (NO)- and NO-dependent mechanisms. Preliminary data suggest that standard aspirin therapy for prevention of atherothrombotic disease severely attenuates reflex cutaneous vasodilation in middle-aged human skin (58¿3 years). Aspirin therapy may inhibit COX isoforms in platelets and vascular tissue, thus blocking a key enzyme involved in VD. Alternatively, platelet activation during heat stress may release substances mediating pathways contributing to VD. We will examine the roles of platelets and vascular COX on reflex VD using systemic interventions (low-dose aspirin and/or platelet inhibitor, clopidogril bisulfate) coupled with a localized examination of NOS- and COX-derived vasodilators.
Hypothesis 1: Low-dose aspirin (81 mg) will attenuate reflex cutaneous vasodilation through COX-dependent mechanisms.
Hypothesis 2: Specific platelet inhibition with clopidogrel bisulfate will not attenuate reflex cutaneous vasodilation.
After screening subjects undergo baseline testing (no oral pharmacologics) incorporating cutaneous microdialysis (MD), whole body heating, and laser Doppler flowmetry. For the testing procedure, four intradermal microdialysis probes will be placed in the skin. Microdialysis sites are assigned drug treatments to serve as to serve as Control, nitric oxide synthase-inhibited (NOS-I), COX-inhibited (COX-I) and NOS and COX inhibited (NOS-I+COX-I). Then subjects enter the double-blind crossover design study with 81 mg of aspirin and/or 75 mg of clopidogrel bisulfate (Plavix ¿). Subjects take each drug for 7 days followed by a 2 week washout before the start of the other drug. Analyses include three-way repeated measures ANOVA. PROC MIXED procedure in SAS.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LACY HOLOWATZ其他文献
LACY HOLOWATZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LACY HOLOWATZ', 18)}}的其他基金
ARGINASE & NO SYNTHASE & ACTIVITY IN SKIN: EFFECTS OF ESSENTIAL HYPERTENS & AGE
精氨酸酶
- 批准号:
7951324 - 财政年份:2009
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH HYPERTENSIO
高血压对反射性皮肤血管舒张无贡献的机制
- 批准号:
7951321 - 财政年份:2009
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF THE NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH AGE
随年龄增长无反射性皮肤血管舒张的机制
- 批准号:
7951319 - 财政年份:2009
- 资助金额:
$ 2.91万 - 项目类别:
ARGINASE & NO SYNTHASE & ACTIVITY IN SKIN: EFFECTS OF ESSENTIAL HYPERTENS & AGE
精氨酸酶
- 批准号:
7625850 - 财政年份:2007
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH HYPERTENSIO
高血压对反射性皮肤血管舒张无贡献的机制
- 批准号:
7625829 - 财政年份:2007
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF THE NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH AGE
随年龄增长无反射性皮肤血管舒张的机制
- 批准号:
7625825 - 财政年份:2007
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF THE NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH AGE
随年龄增长无反射性皮肤血管舒张的机制
- 批准号:
7378541 - 财政年份:2006
- 资助金额:
$ 2.91万 - 项目类别:
MECHANISMS OF NO-CONTRIBUTION TO REFLEX CUTANEOUS VASODILATION WITH HYPERTENSIO
高血压对反射性皮肤血管舒张无贡献的机制
- 批准号:
7378545 - 财政年份:2006
- 资助金额:
$ 2.91万 - 项目类别:
相似国自然基金
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:0.0 万元
- 项目类别:省市级项目
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
- 批准号:81800915
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
- 批准号:81760190
- 批准年份:2017
- 资助金额:32.0 万元
- 项目类别:地区科学基金项目
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
- 批准号:81600879
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
- 批准号:30972889
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
- 批准号:30873099
- 批准年份:2008
- 资助金额:35.0 万元
- 项目类别:面上项目
相似海外基金
Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
- 批准号:
10644089 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events
阿司匹林、Lp(a) 和心血管事件的一级预防
- 批准号:
10720757 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
阿司匹林用于脂蛋白升高患者心血管疾病的一级预防(a)
- 批准号:
10739016 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
PARTUM(产后阿司匹林减少血栓栓塞过度发病率)试验
- 批准号:
498295 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Operating Grants
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
患有阿尔茨海默病和相关痴呆症的老年人停用阿司匹林的健康结果
- 批准号:
10662129 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
A study on the use of aspirin mini tablets for children with Kawasaki disease for the practical application of mini tablets
阿司匹林迷你片在川崎病患儿中的应用研究
- 批准号:
23K16462 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Is Aspirin a Cost-Effective Thromboprophylaxis Alternative for Orthopaedic Trauma Patients?
阿司匹林是骨科创伤患者经济有效的血栓预防替代方案吗?
- 批准号:
10784156 - 财政年份:2023
- 资助金额:
$ 2.91万 - 项目类别:
Aspirin and severe maternal morbidity and mortality and adverse pregnancy outcomes
阿司匹林与严重孕产妇发病率和死亡率以及不良妊娠结局
- 批准号:
469014 - 财政年份:2022
- 资助金额:
$ 2.91万 - 项目类别:
Operating Grants
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
- 批准号:
10152090 - 财政年份:2021
- 资助金额:
$ 2.91万 - 项目类别: